A single-dose, randomized, two-period, two-sequence, crossover pilot bioequivalence study on formulations containing rivaroxaban and acetylsalicylic acid in healthy volunteers under fasting conditions.
01/2023/Pozlab
Phase 1 other active
Quick answer
A single-dose, randomized, two-period, two-sequence, crossover pilot bioequivalence study on formulations containing rivaroxaban and acetylsalicylic acid in healthy volunteers under fasting conditions. for increased blood clotting is a Phase 1 program (other) at s.r.o. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- s.r.o.
- Indication
- increased blood clotting
- Phase
- Phase 1
- Modality
- other
- Status
- active